Correlates of electroencephalographic resting states and erythrocyte membrane docosahexaenoic and eicosapentaenoic acid levels in individuals at ultra-high risk of psychosis

Australian and New Zealand Journal of Psychiatry

Volumn 50, Issue 1, 2016, Pages 56-63

  Lavoie, Suzie ^a,b   Whitford, Thomas J ^c   Benninger, Franz ^d   Feucht, Martha ^e   Kim, Sung Wan ^f   Klier, Claudia M ^e   Mcnamara, Robert K ^g   Rice, Simon ^a,b   Schäfer, Miriam R ^a,b   Amminger, G Paul ^a,b  

^a THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^f Chonnam National University Medical School   (South Korea)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Docosahexaenoic acid; eicosapentaenoic acid; omega 3 polyunsaturated fatty acids; resting EEG; ultra high risk of psychosis; vigilance

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

ADOLESCENT; ADULT; ALERTNESS; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; CELL LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; ELECTROENCEPHALOGRAPHY; ERYTHROCYTE MEMBRANE; FEMALE; FRONTAL LOBE; HIGH RISK POPULATION; HUMAN; LIPID BRAIN LEVEL; MAJOR CLINICAL STUDY; MALE; OCCIPITAL LOBE; PARIETAL LOBE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTING STATE NETWORK; STEADY STATE; THETA RHYTHM; ULTRA HIGH RISK POPULATION; BRAIN; METABOLISM; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM; RISK; SCHIZOPHRENIA;

ADOLESCENT; BRAIN; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ELECTROENCEPHALOGRAPHY; ERYTHROCYTE MEMBRANE; FEMALE; HUMANS; MALE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA;

EID: 84952008941     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867415571168     Document Type: Article

References (36)

1. Amminger GP, Schafer MR, Klier CM, et al. (2012). Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Molecular Psychiatry 17: 1150-1152
2. Amminger GP, Schafer MR, Papageorgiou K, et al. (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry 67: 146-154
3. Berger GE, Wood SJ, Wellard RM, et al. (2008). Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study. Neuropsychopharmacology 33: 2467-2473
4. Boutros NN, Arfken C, Galderisi S, et al. (2008). The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophrenia Research 99: 225-237
5. Calon F, Lim GP, Morihara T, et al. (2005). Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimers disease. European Journal of Neuroscience 22: 617-626
6. Chalon S. (2006). Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins, Leukotrienes & Essential Fatty Acids 75: 259-269
7. Crawford MA. (2006). Docosahexaenoic acid in neural signaling systems. Nutrition and Health 18: 263-276
8. Emsley R, Myburgh C, Oosthuizen P, et al. (2002). Randomized, placebocontrolled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. American Journal of Psychiatry 159: 1596-1598
9. Fekete K, Marosvolgyi T, Jakobik V, et al. (2009). Methods of assessment of n-3 long-chain polyunsaturated fatty acid status in humans: a systematic review. American Journal of Clinical Nutrition 89: 2070S-2084S
10. Fenton WS, Hibbeln J and Knable M. (2000). Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 47: 8-21
11. Fontani G, Corradeschi F, Felici A, et al. (2005). Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. European Journal of Clinical Investigation 35: 691-699
12. Galderisi S, Mucci A, Volpe U, et al. (2009). Evidence-based medicine and electrophysiology in schizophrenia. Clinical EEG and Neuroscience 40: 62-77
13. Hoen WP, Lijmer JG, Duran M, et al. (2013). Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta-Analysis. Psychiatry Research 207: 1-12
14. Horrobin DF, Glen AI and Vaddadi K. (1994). The membrane hypothesis of schizophrenia. Schizophrenia Research 13: 195-207
15. Joy CB, Mumby-Croft R, and Joy LA. (2003). Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews 3: CD001257
16. Laufs H. (2008). Endogenous brain oscillations, and related networks detected by surface EEG-combined fMRI. Human Brain Mapping 29: 762-769
17. Laufs H, Krakow K, Sterzer P, et al. (2003). Electroencephalographic signatures of attentional, and cognitive default modes in spontaneous brain activity fluctuations at rest. Proceedings of the National Academy of Sciences of the United States of America 100: 11053-11058
18. Lavoie S, Schafer MR, Whitford TJ, et al. (2012). Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis. Schizophrenia Research 138: 206-211
19. McNamara RK, Able J, Jandacek R, et al. (2010). Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. American Journal of Clinical Nutrition 91: 1060-1067
20. Mellor JE, Laugharne JD, and Peet M. (1995). Schizophrenic symptoms, and dietary intake of n-3 fatty acids. Schizophrenia Research 18: 85-86
21. Palva S, and Palva JM. (2007). New vistas for alpha-frequency band oscillations. Trends in Neuroscience 30: 150-158
22. Peet M, and Horrobin DF. (2002). A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36: 7-18
23. Peet M, Laugharne JD, Mellor J, et al. (1996). Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients and the clinical effects of dietary supplementation. Prostaglandins, Leukotienes, and Essential Fatty Acids 55: 71-75
24. Prior PL, and Galduroz JC. (2012). (N-3) Fatty acids: molecular role, and clinical uses in psychiatric disorders. Advances in Nutrition 3: 257-265
25. Richardson AJ, Allen SJ, Hajnal JV, et al. (2001). Associations between central, and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy, and fatty acid composition of erythrocyte membranes. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25: 1513-1521
26. Smesny S, Milleit B, Hipler UC, et al. (2014). Omega-3 fatty acid supplementation changes intracellular phospholipase A activity, and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Molecular Psychiatry 19: 317-324
27. Sublette ME, Milak MS, Hibbeln JR, et al. (2009). Plasma polyunsaturated fatty acids, and regional cerebral glucose metabolism in major depression. Prostaglandins, Leukotienes, and Essential Fatty Acids 80: 57-64
28. Sumich A, Matsudaira T, Gow RV, et al. (2009). Resting state electroencephalographic correlates with red cell long-chain fatty acids, memory performance, and age in adolescent boys with attention deficit hyperactivity disorder. Neuropharmacology 57: 708-714
29. van der Kemp WJ, Klomp DW, Kahn RS, et al. (2012). A meta-Analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophrenia Research 141: 153-161
30. Wood SJ, Cocchi L, Proffitt TM, et al. (2010). Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study. Psychiatry Research 182: 180-182
31. Yehuda S, Rabinovitz S, Carasso RL, et al. (2002). The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiology of Aging 23: 843-853
32. Yung AR, McGorry PD, McFarlane CA, et al. (1996). Monitoring, and care of young people at incipient risk of psychosis. Schizophrenia Bulletin 22: 283-303
33. Yung AR, Nelson B, Stanford C, et al. (2008). Validation of prodromal criteria to detect individuals at ultra high risk of psychosis:2 year follow-up. Schizophrenia Research 105: 10-17
34. Yung AR, Phillips LJ, Yuen HP, et al. (2003). Psychosis prediction: 12-month follow up of a high-risk (prodromal) group. Schizophrenia Research 60: 21-32
35. Yung AR, Yuen HP, McGorry PD, et al. (2005). Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Australian, and New Zealand Journal of Psychiatry 39: 964-971
36. Zimmermann R, Gschwandtner U, Wilhelm FH, et al. (2010). EEG spectral power, and negative symptoms in at-risk individuals predict transition to psychosis. Schizophrenia Research 123: 208-216